First‑Line Antidepressant Therapy for Fibromyalgia with Comorbid Depression

First‑Line Recommendation (CDC, EULAR, VA/DoD)

Duloxetine is FDA‑approved for fibromyalgia and is the preferred first‑line antidepressant for adults with fibromyalgia and co‑occurring depression; CDC 2022 guidelines assign it a strong recommendation and report small‑to‑moderate improvements in pain, functional status, and quality of life. 1

Initiate duloxetine at 30 mg once daily for the first week to reduce the incidence of nausea, then increase to 60 mg daily; the therapeutic dose range is 60–120 mg daily. This regimen is supported by moderate‑quality evidence. 3
Duloxetine provides concurrent treatment of major depressive disorder and generalized anxiety disorder while alleviating fibromyalgia pain, based on moderate‑quality clinical data. 3
The drug does not cause clinically important electrocardiographic changes or blood‑pressure elevations, and routine monitoring of liver aminotransferases is unnecessary; safety profile is considered strong. 3

Milnacipran is also FDA‑approved for fibromyalgia and demonstrates efficacy comparable to duloxetine; current CDC and EULAR guidelines give it an equal strength recommendation as a first‑line SNRI. 6

Amitriptyline is recommended as a second‑line agent when duloxetine is contraindicated or not tolerated; guideline panels assign it a moderate recommendation. 6
Start with 10–25 mg at bedtime, titrate every 3–5 days as tolerated, and aim for a target dose of 25–50 mg nightly; a therapeutic trial should last 6–8 weeks, including at least 2 weeks at the highest tolerated dose. Evidence quality is moderate. 4

Tricyclic antidepressants, including amitriptyline, are potentially inappropriate for adults ≥ 65 years because of anticholinergic adverse effects (sedation, dry mouth, urinary hesitancy, constipation). This is a strong recommendation. 1

Use amitriptyline with caution in patients with ischemic heart disease or ventricular conduction abnormalities; obtain a screening ECG for patients > 40 years and limit the dose to < 100 mg/day when possible. Evidence is moderate. 3

Selective serotonin‑reuptake inhibitors (SSRIs) are not recommended as first‑line therapy for fibromyalgia because their effect sizes for pain are smaller than those of SNRIs or tricyclics. 6
Long‑term use of strong opioids is discouraged; VA/DoD guidelines explicitly recommend against chronic opioid therapy for fibromyalgia. This is a strong recommendation. 8

Step 1 – Duloxetine: 30 mg daily for 1 week, then 60 mg daily. If partial response at 4–6 weeks, increase to 90–120 mg daily. Strong recommendation. 3
Step 2 – Alternative or Adjunct: Switch to milnacipran or start amitriptyline 25–50 mg at bedtime (preferred if insomnia is prominent). Avoid amitriptyline in patients ≥ 65 years or with cardiac disease. Moderate recommendation. 6
Step 3 – Augmentation: For partial duloxetine response, add pregabalin (FDA‑approved for fibromyalgia) rather than switching agents. Moderate recommendation. 9

Patients with both fibromyalgia and depression are more likely to experience clinically meaningful benefit from antidepressant therapy, reinforcing the importance of treating depressive symptoms alongside pain. Moderate evidence. 1

All major guidelines emphasize that optimal management requires combining antidepressants with aerobic exercise, cognitive‑behavioral therapy, and other non‑pharmacologic interventions; this is a strong recommendation. 1